134 and 70% female. Would Teva even pursue it?
I'm relying on Alan Hobbes here. He states that 70% of Cushing's patients are female. He also states, and this goes against common sense, that even though 134 will be a superior drug to Kormlyn that will have a lower cost of goods sold in that there will be no need to have "white glove" service.
It appears that 134 is completely on track and that its benefits are even superior than what was initially thought. If 134 gets approved, would Teva even bother going through with generic Kormlyn? Wouldn't Kormlyn be completely obsolete at that time.
That said, doesn't cost that much to put a pole in the ice and start the clock running in the event that 134 fails.
And--out of nowhere--there will be cancer information before the end of 2018?
Stunned by how good the information was last night. I told my wife--didn't know who had a better night last night, CORT or both Russian female skaters.